USPTO serial 87114798
AUREALIS PHARMA
Reviewed by CopyMark Law Group
Reg. 5383359Status 710
- Filing date
- Status date
- Registration date
- Jan 23, 2018
- Examiner
- AIKENS, RONALD E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with AUREALIS PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Glenn Schroeder
R. GLENN SCHROEDER SCHROEDER LAW PC110 COOPER STREET #605BABYLON, NY 11702UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; sanitary preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; dietetic food and substances, namely, fermented milk products, drinks and gum, adapted for medical or veterinary use; dietary supplements for humans and animals; health care products, namely, plasters, materials for dressings, ointments, sprays, injections, human therapeutics, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; disinfectants; preparations for destroying vermin; fungicides and herbicides; pharmaceuticals, biosimilars, medicine, drugs, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint modifiers, vaccines, for human beings and animals; prokaryotic organisms, namely, genetically modified bacteria, bacteria producing growth factors, antibodies, immunomodulators, anticancer agents, checkpoint inhibitors and checkpoint modifiers and vaccines; medicines for human purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; medicines for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; bacteriological preparations for medical and veterinary use, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for pharmaceutical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; pharmaceutical and veterinary preparations and substances in particular for the treatment of cancer, inflammatory diseases, immune system related diseases, specifically autoimmune disorders, and other conditions which can be treated or ameliorated by antibodies or antibody fragments binding to, activating or blocking of a target antigen or ameliorated by immunomodulating factors, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 2, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 23, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 23, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 15, 2017 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 12, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 17, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 17, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 11, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 16, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 16, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 10, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jul 14, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 12, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 12, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 12, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 9, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 10, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 10, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 10, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 28, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 28, 2016 | NWAP | NEW APPLICATION ENTERED | — |